CAR T cell News and Research

RSS

MIT researchers develop method to isolate T cells primed for certain allergies or infections

When your immune system is exposed to a vaccine, an allergen, or an infectious microbe, subsets of T cells that can recognize a foreign intruder leap into action.

19 Nov 2019

Deterministic mechanoporation of cells en masse to cure cancer

What if you could cure cancer by re-engineering patients' cells to better target and destroy their own tumors? With the advent of powerful new cellular engineering technologies, this is no longer the stuff of science fiction.

13 Nov 2019

Penn researchers tag CAR T cells with imaging markers to monitor cancer therapy

With CAR T cell therapy, a patient's own immune cells are genetically modified and inserted back into the body to find and kill cancer. This form of immunotherapy has already revolutionized some cancer treatments, but once the CAR T cells are inside a patient, where do they go? How do doctors know that they have successfully reached their target and that they are continuing to fight disease weeks, months, or even years later?

5 Nov 2019

MD Anderson and Takeda announce agreement to develop off-the-shelf CAR NK-cell therapy platform

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, 'armored' with IL-15, for the treatment of B-cell malignancies and other cancers.

5 Nov 2019

Researchers develop new type of transposase protein with improved biochemical properties

The team, comprising researchers from the European Molecular Biology Laboratory, the Universitätsklinikum Würzburg and the Paul-Ehrlich-Institut, managed to design a new variant of the Sleeping Beauty transposase with dramatically improved biochemical properties.

4 Nov 2019

Three UCLA researchers receive multimillion-dollar grant from state's stem cell agency

Three researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received awards totaling more than $18 million from the California Institute for Regenerative Medicine, the state's stem cell agency.

31 Oct 2019

UCLA prostate cancer program receives $8.7 million grant from NCI

The prostate cancer program at the UCLA Jonsson Comprehensive Cancer Center and UCLA Health has been awarded an $8.7 million Specialized Program of Research Excellence, or SPORE, grant from the National Cancer Institute.

31 Oct 2019

NYU researcher awarded $1.7 million NIH grant to optimize cancer treatment

Weiqiang Chen, assistant professor of biomedical engineering and mechanical and aerospace engineering at the NYU Tandon School of Engineering, has been awarded the Maximizing Investigators' Research Award (R35) from the National Institute of General Medical Sciences, a division of the National Institutes of Health.

29 Oct 2019

Phase 2 clinical trial of CAR T-cell therapy starts at Atlantic Health System

Atlantic Health System is treating patients in a new Phase 2 clinical trial of CAR T-cell therapy at Morristown Medical Center. A select number of sites across the U.S. are involved in this study, which is done on an outpatient basis.

25 Oct 2019

ConvertibleCAR immunotherapy can be used to attack HIV latent reservoir

A team of Gladstone scientists and their partners at Xyphos Biosciences, Inc. describe a new way of attacking cells infected by HIV in this week's issue of the journal Cell.

24 Oct 2019

Scientists harness the power of immune system to test novel cancer treatment

The field of immunotherapy has revolutionized the way people with incurable cancers are treated, saving the lives of many people whose disease would have otherwise been seen as a death sentence. Despite its success in treating people with deadly forms of leukemia and lymphoma, there are still many people who do not benefit from the treatment or eventually experience a relapse of their cancer.

16 Oct 2019

Drug-light combination could offer better control over CAR T-cell treatments

Bioengineers at the University of California San Diego are a step closer to making CAR T-cell therapy safer, more precise and easy to control.

15 Oct 2019

NUS researcher invents novel transfection technique to deliver DNA into immune cells

Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.

4 Oct 2019

CAR T-cell therapy may be effective in killing solid tumor cells

There is now a multitude of therapies to treat cancer, from chemotherapy and radiation to immunotherapy and small molecule inhibitors. Chemotherapy is still the most widely used cancer treatment, but chemotherapy attacks all the rapidly dividing cells that it locates within the body, whether they're ultimately harmful or beneficial.

2 Oct 2019

Cancer Research Institute declares 2019 recipients of top scientific and philanthropic awards

The Cancer Research Institute (CRI), a nonprofit organization dedicated to advancing the discovery and development of powerful immunotherapies for all forms of cancer, has announced the 2019 recipients of its highest scientific and philanthropic awards.

27 Sep 2019

Scientists use CAR-T cells to reverse cardiac fibrosis

Scientists have used CAR-T cell therapy to treat cardiac fibrosis, a key part of heart disease and cardiac arrest.

12 Sep 2019

CAR T-cell therapy may be viable treatment option for heart disease

CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients' own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition: heart disease.

12 Sep 2019

Super-powered immune cells to attack tumors

Ground-breaking immune therapy promises to deliver vital evidence in the fight against cancer as researchers from the Centre for Cancer Biology open a new clinical trial using genetically engineered immune cells to treat solid cancers.

23 Aug 2019

New circulating immune cell could help predict type 1 diabetes risk

A new Finnish study suggests that type 1 diabetes may in part be caused by a novel subset of immune cells. This is because these cells, called peripheral T helper cells, are found to circulate at a higher rate in children with type 1 diabetes of recent onset, as well as in healthy children who later develop the condition.

20 Aug 2019

ISCT expresses concern about companies offering unproven T-cell preservation services

ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces its objection to linking the benefits of cellular immunotherapy, in particular Chimeric Antigen Receptor (CAR) T-cell therapy, with recent market offerings for third party cryopreserving and banking of T-cells for future therapeutic use.

8 Aug 2019